{"doi":"10.1210/clinem/dgae845","title":"Feasibility, Acceptability, and Validity of Home Continuous Glucose Monitoring–Based Oral Glucose Tolerance Test in Youth","abstract":"CONTEXT: Home-based approaches to type 2 diabetes (T2D) screening in youth may facilitate early diagnosis. OBJECTIVE: This work aimed to evaluate feasibility, acceptability, and validity of a continuous glucose monitoring (CGM)-based oral glucose tolerance test (OGTT). METHODS: A prospective observational study was conducted at a pediatric clinical and translational research center. Participants were youth aged 8 to 18 years with overweight/obesity and prediabetes-range glycated hemoglobin A1c (HbA1c), fasting glucose, or 2-hour glucose on OGTT, and/or one or more guideline-based T2D risk factors. Participants completed two 75 g 2-hour OGTT 1) at the research center using serum samples (research-OGTT), and 2) at home using blinded CGM (home-OGTT). Feasibility: Percentage with valid home-OGTT data (date/time reported, transmitter returned). Acceptability: Survey and interview responses. Validity: Sensitivity, specificity, positive- and negative predictive value (PPV, NPV) of home- vs research-OGTT dysglycemia (fasting ≥100 mg/dL; 2-hour ≥140 mg/dL). RESULTS: Thirty-nine youth (54% female; 33% Black, 8% Hispanic/Latinx, 13% multiracial, 46% non-Hispanic White; age 14.6 ± 2.0 years; mean body mass index 37.0 ± 6.7 kg/m2) participated. HbA1c was 5.7% ± 0.4%, fasting glucose 85.7 ± 8.0 mg/dL, and 2-hour glucose 115.9 ± 25.9 mg/dL. Thirty (77%) had valid home-OGTT data. Acceptability was high (92% excellent/great, 8% neutral). Due to higher average values on home-OGTT, sensitivity and NPV were high (≥80%), while specificity (fasting: 10%; 2-hour: 25%) and PPV (fasting: 3.6%, 2-hour: 18.2%) were low. CONCLUSION: Home-OGTT was acceptable, but strategies to precisely capture glucose ingestion timing could improve feasibility. Alternate dysglycemia thresholds may need to be defined prior to using CGM as a method for T2D screening in youth.","journal":"The Journal of Clinical Endocrinology & Metabolism","year":2024,"id":478127,"datarank":0.16479184330021646,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"self_citation_contribution":0.16479184330021646,"citation_network_contribution":0.0,"self_endowment_contribution":0.16479184330021646,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9535,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1263706,"name":"Caleb Harrison","orcid":null,"position":1,"is_corresponding":false},{"id":965280,"name":"Brianna Hewitt","orcid":null,"position":2,"is_corresponding":false},{"id":1316996,"name":"Jennifer L Mejier","orcid":null,"position":3,"is_corresponding":false},{"id":453634,"name":"Mary Ellen Vajravelu","orcid":"0000-0002-5839-7923","position":4,"is_corresponding":false},{"id":1064261,"name":"Adriana Rodriguez Gonzalez","orcid":null,"position":0,"is_corresponding":true}],"reference_count":24,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T02:06:42.155024Z","pmid":"39657252","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}